Equities

Microbot Medical Inc

Microbot Medical Inc

Actions
  • Price (EUR)0.8715
  • Today's Change0.016 / 1.81%
  • Shares traded--
  • 1 Year change-27.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Microbot Medical Inc. is a pre-clinical medical device company. The Company is specializing in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is primarily focused on leveraging its robotic technologies with surgical robotics to improve surgical outcomes for patients. Its technological platforms include LIBERTY and NovaCross. Using its LIBERTY Endovascular Robotic Surgical System, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. LIBERTY Endovascular Robotic Surgical System addresses the needs of interventional cardiology, interventional radiology and interventional neuroradiology markets.

  • Revenue in USD (TTM)0.00
  • Net income in USD-11.21m
  • Incorporated1988
  • Employees22.00
  • Location
    Microbot Medical Inc25 RECREATION PARK DR SUITE 108HINGHAM 02043United StatesUSA
  • Phone+1 (908) 938-5561
  • Fax+1 (302) 655-5049
  • Websitehttp://www.microbotmedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.